McDermott Advises Vetoquinol in its Acquisition from Elanco Animal Health of the Rights to Two Product Families for Europe and the United Kingdom - McDermott Will & Emery

McDermott Advises Vetoquinol in its Acquisition from Elanco Animal Health of the Rights to Two Product Families for Europe and the United Kingdom

Overview


McDermott Will & Emery advised Vetoquinol in the signing of an agreement for the acquisition of the European and UK rights to the Profender® and Drontal® product families from Elanco Animal Health for a total cash price of $140 million. As this transaction is linked to Elanco’s acquisition of Bayer AG’s Animal Health, which is subject to regulatory approval by the European Commission and the US Federal Trade Commission, it is expected to close in mid-2020.

McDermott Will & Emery acted for Vetoquinol with a Paris team composed of Antoine Vergnat, Anthony Paronneau and Lionel Lesur, (partners), Anne-France Moreau (counsel), and Katya Ascher, Côme de Saint Vincent, Edouard Becker and Sarah Candelibes (associates) and the team in New York led by Meir Lewittes (partner) and Griffin Doty (associate).

About McDermott


McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With 20 locations on three continents, our team works seamlessly across practices, industries and geographies to deliver highly effective—and often unexpected—solutions that propel success. More than 1,100 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.